Aguirre Jarrad Mattieu's Form 4 filing
Lyell Immunopharma, Inc. (LYEL) · filed Sep 10, 2026
- Accession no.
- 0002150331-26-000002
- Filed
- Sep 10, 2026, 7:31 PM ET
- Trade date
- Sep 10, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 0 non-derivative transactions and 1 derivative transaction. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Aguirre Jarrad MattieuCIK 0002150331 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Common Stock | AGrant or awardAcquired | +47,500 | $0.00 | $0 | 47,500 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.